RNN, HIRU, PDS, PWRM, HMN - Stock Report From DrStockPick.com!

Nov. 6, 2010 - PRLog -- HIRU CORPORATION (Other OTC- HIRU.PK) and its primary subsidiary, Jiangxi Shuangshi Animal Health Products Co. (also known as Shuangshi AHP Co.) serve the Chinese agricultural market at home. The Company focuses on developing, manufacturing and marketing a wide variety of veterinary products to the agricultural industry and has a solid reputation in the Chinese animal husbandry industry for offering quality products and solutions to farmers across the nation. Indeed, the Company was awarded the prestigious Good Manufacturing Practice Certificate in 2005 and continues to expand its development and research to offer more and improved product lines for the Chinese agricultural industry.

Shuangshi AHP is not only part of Hiru Corp., it is also part of an industrial conglomerate known as Jiangxi Animal Health Products Co. Group. The Group anticipates realizing $227 million RMB (approximately $33 million USD) in annual sales, with average annual profits breaking approximately $66.5 million RMB (or $9.5 million USD), 30% of which is due to the efforts of Shuangshi AHP.

The Group chose Shuangshi AHP to join Hiru Corp. to enter the US markets with the belief that if the US market responds favorably to the company, and its business model and marketing strategy, the rest of the conglomerate will follow suit. Shuangshi AHP is using its presence on the US market to expand its Research and Development division so that it can introduce new veterinary medications to the Chinese industry in the coming years.

***************************************



Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.

Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

"We are very excited to be acquiring Rozetta-Cell Life Sciences," stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. "Rozetta-Cell brings us a tremendous amount of complementary adult stem cell therapy technology, know-how and experience. With the addition of Rozetta-Cell, Power3 will significantly strengthen its IP portfolio in a major growth market by merging regenerative medicine with the technologies that we are using to identify disease-specific protein biomarkers and develop them into screening and diagnostic tests to address unmet medical needs."

Completion of the merger is subject to customary closing conditions, including receipt by the parties of all necessary board and shareholder approvals and third party consents. There can be no assurance that these conditions will be met or that the merger will be completed.

***************************************

Horace Mann Educators Corporation  recently reported net income of $20.1 million (49 cents per share) and $65.7 million ($1.61 per share) for the three and nine months ended September 30, 2010, compared to $19.3 million (48 cents per share) and $51.3 million ($1.27 per share) for the same periods in 2009.

Horace Mann Educators Corporation, through its subsidiaries, markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance in the United States.

***************************************

Precision Drilling Corporation  recently announced plans to commence a private offering of US$550 million aggregate principal amount of senior unsecured notes due 2020. Precision intends to use the net proceeds from the proposed notes offering, together with cash on hand, to repay in full its outstanding indebtedness under its existing term loan A and term loan B credit facilities.

Precision Drilling Corporation, through its subsidiaries, provides onshore drilling, well servicing, and ancillary oilfield services to the oil and gas industry primarily in Canada and the United States.

***************************************

Rexahn Pharmaceuticals, Inc. , a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced recently that it has been awarded grants totaling $822,137 through the US Federal Government’s Qualifying Therapeutic Discovery Project.

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system disorders, sexual dysfunction, and other unmet medical needs in the United States.

******************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Hiru Corporation (HIRU.PK)

Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (PWRM.OB).